MedTrace Logo

The Effects of NVX-108 as a Radiation Sensitizer in Glioblastoma

NCT02189109 · Status: COMPLETED · Phase: PHASE1 · Type: INTERVENTIONAL · Enrollment: 11

Last updated 2019-02-28

No results posted yet for this study

Summary

This clinical trial is testing the safety, tolerability and effectiveness of NVX-108 administered via intravenous infusion in combination with standard radiation and chemotherapy.

NVX-108 is being developed to increase the amount of oxygen delivered to tumors which is hoped to increase the effectiveness of radiation therapy.

Conditions

Interventions

DRUG

NVX-108

0.2% emulsion administered i.v.

Sponsors & Collaborators

  • The Alfred

    collaborator OTHER

  • NuvOx LLC

    lead INDUSTRY

Principal Investigators

  • Jason Lickliter, MBBSPhDFRACP · Nucleus Network

Study Design

Allocation
NA
Purpose
TREATMENT
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
18 Years
Max Age
70 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2014-05-31
Primary Completion
2017-08-31
Completion
2018-04-30

Countries

  • Australia

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT02189109 on ClinicalTrials.gov